ArticleFrontiers in oncology2024
Global burden of disease study analysis of thyroid cancer burden across 204 countries and territories from 1990 to 2019.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Tracheal intubation in the thyroid surgical position improves recurrent laryngeal nerve monitoring: a dual-center randomized trial.International journal of surgery (London, England) · 2026Trial
- Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer.Annals of nuclear medicine · 2026Article
- Inflammatory proteins in pre-diagnosis versus at-diagnosis samples associated with differentiated thyroid cancer.International journal of cancer · 2026Observational
- Spatial and temporal distribution of thyroid cancer incidence in China: An ecological study based on a national registry.PloS one · 2026Article
- Bioinformatics analysis reveals C5AR1's impact on thyroid cancer development via immune infiltration.Scientific reports · 2025Article
- Diverging spatiotemporal trajectories of thyroid cancer incidence and mortality in reproductive-age women: a socio-demographic index stratified analysis of GBD 2021 data.Gland surgery · 2025Article
- Incidental Detection of Situs Inversus Totalis During Preoperative Evaluation for Thyroid Cancer: A Case Report.Cureus · 2025Article
- Thyro-GenAI: A Chatbot Using Retrieval-Augmented Generative Models for Personalized Thyroid Disease Management.Journal of clinical medicine · 2025Article
- Serum Biomarkers in Thyroid Malignancies: Evaluating Thyroid-Stimulating Hormone Receptor (TSHR) and Vascular Adhesion Protein-1 (VAP-1) as Potential Diagnostic Biomarker.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Local and Loco-Regional Anesthesia in Patients Who Underwent Thyroid and Parathyroid Surgery.Journal of clinical medicine · 2025Review
- Assessing the Rise in Papillary Thyroid Cancer Incidence: A 38-Year Australian Study Investigating WHO Classification Influence.Journal of epidemiology and global health · 2025Article
- Global burden of polycystic ovary syndrome, uterine cancer and diabetes mellitus type 2 among women of childbearing age: trends in incidence, prevalence, mortality, and disability-adjusted life-years from 1990 to 2021.Frontiers in medicine · 2025Article
- A comprehensive analysis and comparative study of the trends in thyroid cancer burden in China and globally from 1990 to 2021, with projections for the next 15 Years.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this study is to assess the burden of thyroid cancer over the course of 30 years in 204 countries and territories. Methods: Data from the Global Burden of Disease (GBD) 2019 database was analyzed to extract information on prevalence, deaths, DALYs(disability-adjusted life-years), YLL(years of life los), YLD(years lived with disability), and their corresponding age-standardized rates at global, regional, and national levels. The primary focus of the study was to examine trends in thyroid cancer from 1990 to 2019, specifically looking at the Estimated Annual Percentage Change (EAPC) for ASPR, ASDR, and ASDR. Additionally, the study investigated the relationship between cancer burden and the Socio-Demographic Index (SDI). Results: Globally, there will be approximately 18.3 million thyroid cancer (TC) cases in 2019; China and the USA are projected to be the most significant with 310,327 and 220,711 cases (16.17 and 14.82 cases per 100,000 people, respectively).Over the period from 1990 to 2019, age-standardized prevalence rates exhibited a global rise, whereas deaths and DALYs saw a decrease(EAPC:1.63, -0.15- -0.14, respectively). Significantly, the age-standardized prevalence rate increased in 21 GBD regions, affecting 195 out of 204 countries or territories. Over the studied period, thyroid cancer cases, deaths, and DALYs were consistently higher among females than males. Furthermore, a higher Socio-demographic Index was associated with increased age-standardized prevalence rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.